… The role of β-lactam-β-lactamase inhibitors (BLBLIs) are … a β-lactam is formulated with
a β-lactamase inhibitor to extend the spectrum of activity and retain the activity of the β-lactam …

… while duration of b-lactamase inhibitor therapy was significantly … (odds ratio [OR] Å 1.19),
while b-lactamase inhibitor therapy … for nosocomial tended-spectrum b-lactamases (ESBLs), …

… when both the fCss/MIC BP ratio of PIP was ≥4 (where MIC … 8 mg/L) and the fCss/C T ratio
of TAZ was ≥1 (where C T was the … Css PIP to Css TAZ ratios were calculated (PIP:TAZ ratio) …

… After adjustment for confounders, no association was found between either empirical therapy
with BLBLI (adjusted hazard ratio [HR], 1.14; 95% confidence interval [CI], .29–4.40; P = .84…

… in a multivariable analysis, adjusting for the propensity score, included exposure to β-lactam-β-lactamase
inhibitor combinations (odds ratio [OR], 10.17; 95% confidence interval [CI], …

… The main outcome variables were cure/improvement rate at day 14 and all-cause 30-day …
The adjusted odds ratio (OR) (95% confidence interval [CI]) values for cure/improvement rate …

… Carbapenems are the treatment of choice in ESBL-PE infections ( 43 ) and, at the same time,
we found that carbapenems and beta-lactams/beta-lactamase inhibitors increase the risk of …

… Subgroup analysis restricting to pooled odds ratio from random effects model of beta-lactam/beta-lactamase-inhibitors
vs. carbapenem for empiric treatment of ESBL-producing …

… a ratio of … . Extended-Spectrum Beta-Lactamases–Red Española de Investigación en
Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria Group. β-Lactam/β-lactam inhibitor …

… The primary endpoint was the case fatality rate at 30 days from onset of BSI. Secondary
outcomes included the following: (i) 7-day and (ii) 14-day case fatality rates; (iii) persistent BSI; (iv…